[Relationship between lipid and glucose metabolism and bone mineral metabolism : pleiotropic effects of therapeutic agents for diabetes and hyperlipidemia].
Bone mineral metabolism and bone remodeling involve a variety of molecules, for instance, bone morphogenetic proteins (BMPs) , fibroblast growth factors (FGFs) , insulin growth factors (IGFs) , interleukin-1 (IL-1) , prostagrandin E(2) (PGE(2)) , and tumor necrosis factor-alpha (TNF-alpha) . Most of them are also involved in lipid and glucose metabolism. Recent in vitro and in vivo studies have reported that therapeutic agents for diabetes and hyperlipidemia, such as insulin, thiazolidinediones, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have pleiotropic effects on bone mineral metabolism. These agents may be useful tools for treatment of bone and mineral disorders.
Hamada
Yasuhiro
Y
Kobe University School of Medicine, Division of Nephrology and Kidney Center.
Fukagawa
Masafumi
M
D000818:Animals; D015519:Bone Density; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism*; D002113:Calcification, Physiologic / Q000187:drug effects; D050260:Carbohydrate Metabolism; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology; D020738:Leptin / Q000494:pharmacology; D050356:Lipid Metabolism; D010012:Osteogenesis / Q000187:drug effects; D045162:Thiazolidinediones / Q000494:pharmacology
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D020738:Leptin; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione; D005947:Glucose